ProPharma Group Executive and Leadership Team

Jon Otterberg, the Chief Financial Officer at ProPharma Group, manages the fiscal health and capital allocation strategies required to sustain growth in the regulatory consulting sector. Overseeing financial planning and analysis, the Chief Financial Officer ensures that resource distribution aligns with the company's long-term objectives. This leadership role involves monitoring revenue streams across diverse service lines to maintain profitability and operational stability. By optimizing financial reporting processes, Jon Otterberg provides the executive team with actionable insights for strategic decision-making. The Chief Financial Officer collaborates with the Board to evaluate potential acquisitions and market expansion opportunities within the medical industry. Through rigorous budget management, Otterberg supports the scaling of clinical research and compliance services. This commitment to fiscal discipline ensures that ProPharma Group maintains the necessary liquidity to invest in cutting-edge regulatory technologies while delivering consistent value to stakeholders and clients worldwide.

Matthew Weinberg, the President, Regulatory Sciences at ProPharma Group, leads the strategic direction of the regulatory consulting division, ensuring that clients successfully navigate the complexities of medical product approval. Overseeing the development of submission strategies, the President, Regulatory Sciences ensures that all documentation meets stringent global health authority requirements. This leadership role involves managing cross-functional teams that provide expert guidance on clinical trial data and compliance protocols. By streamlining the regulatory pathway, Matthew Weinberg accelerates the time-to-market for critical medical innovations. The President, Regulatory Sciences collaborates with the broader executive team to identify emerging trends in the medical industry and adapt service offerings accordingly. Through the application of deep technical expertise, Weinberg ensures that ProPharma Group delivers precise and reliable regulatory support. This focus on scientific rigor and strategic planning enables the company to maintain its position as a trusted partner for medical organizations seeking to achieve and sustain regulatory compliance.

Daniel Ryan, the President, Clinical Research Solutions at ProPharma Group, directs the operational execution of clinical trials and research programs designed to advance medical knowledge. Overseeing the design and management of complex research projects, the President, Clinical Research Solutions ensures that all studies adhere to the highest ethical and scientific standards. This leadership role involves coordinating with global research sites to optimize trial efficiency and data quality. By leveraging advanced research methodologies, Daniel Ryan facilitates the rapid collection and analysis of clinical evidence. The President, Clinical Research Solutions collaborates with regulatory experts to ensure that trial outcomes support successful product development and approval. Through the implementation of innovative research strategies, Ryan drives the growth of the clinical division and enhances the company's reputation for excellence. This focus on operational precision enables ProPharma Group to provide comprehensive support for medical research initiatives, ultimately contributing to the development of life-saving treatments.

Laura Hopper, the President, Pharmacovigilance at ProPharma Group, manages the safety monitoring and risk management services essential for the ongoing surveillance of medical products. Overseeing the collection and analysis of adverse event data, the President, Pharmacovigilance ensures that clients maintain compliance with global safety reporting regulations. This leadership role involves directing teams that provide real-time monitoring and signal detection to protect patient health. By integrating advanced safety databases and automated reporting tools, Laura Hopper enhances the accuracy and speed of safety assessments. The President, Pharmacovigilance collaborates with regulatory and clinical teams to ensure that safety data informs product development and lifecycle management. Through the application of rigorous safety protocols, Hopper mitigates risk and supports the long-term viability of medical products. This focus on patient safety and regulatory compliance enables ProPharma Group to provide essential pharmacovigilance services that meet the highest industry standards for quality and reliability.

Jason DeGoes, the President at ProPharma Group, oversees the overarching operational strategy and business development initiatives that drive the company's market presence. Directing the integration of various service lines, the President ensures that the organization delivers a cohesive and comprehensive suite of regulatory and compliance solutions. This leadership role involves identifying new market opportunities and fostering strategic partnerships that expand the company's global footprint. By aligning departmental goals with the corporate mission, Jason DeGoes promotes operational synergy and sustainable growth. The President collaborates with the executive team to refine the company's value proposition and maintain a competitive edge in the medical consulting industry. Through the implementation of high-level strategic initiatives, DeGoes ensures that ProPharma Group remains responsive to the evolving needs of its clients. This focus on leadership and organizational alignment enables the company to consistently deliver superior results while navigating the complexities of the global medical regulatory landscape.

James Kolbet, the President Life Science Consulting at ProPharma Group, leads the advisory services division, providing strategic guidance to medical organizations on complex business and operational challenges. Overseeing the delivery of high-level consulting engagements, the President Life Science Consulting ensures that clients receive actionable insights to improve their regulatory and compliance performance. This leadership role involves managing a team of industry experts who specialize in optimizing product development and commercialization strategies. By applying deep domain knowledge, James Kolbet helps clients navigate the intricacies of the medical industry and achieve their strategic objectives. The President Life Science Consulting collaborates with other division leaders to provide integrated solutions that address the full lifecycle of medical products. Through the development of innovative consulting frameworks, Kolbet drives the growth of the advisory practice and enhances the company's reputation for excellence. This focus on strategic consulting enables ProPharma Group to provide comprehensive support that empowers medical organizations to succeed.

Kirk Wroblewski, the Chief Information Officer at ProPharma Group, directs the digital infrastructure and data security protocols essential for regulatory compliance. Overseeing global technology initiatives, the Chief Information Officer ensures that all systems support the rigorous demands of the medical industry. This leadership role involves architecting scalable cloud solutions that facilitate secure data exchange across international markets. By integrating advanced analytics into daily operations, Kirk Wroblewski optimizes internal workflows and enhances service delivery for clients. The Chief Information Officer maintains alignment with the Board regarding cybersecurity investments and long-term digital transformation goals. Through the implementation of robust software frameworks, Wroblewski secures the integrity of sensitive clinical data. This focus on technological innovation drives efficiency across the entire organization, ensuring that ProPharma Group remains at the forefront of digital compliance solutions while supporting the complex needs of global medical partners.

Rachel Bias, the Chief Human Resources Officer at ProPharma Group, architects the talent acquisition and organizational development strategies necessary to support a global workforce of regulatory experts. Overseeing recruitment, retention, and employee engagement, the Chief Human Resources Officer ensures that the company attracts top-tier professionals capable of navigating complex medical compliance challenges. This leadership role involves fostering a culture of continuous learning and professional growth across all departments. By implementing performance management systems, Rachel Bias aligns individual contributions with the broader mission of delivering high-quality regulatory solutions. The Chief Human Resources Officer collaborates with other C-suite leaders to refine organizational structure and promote operational agility. Through the development of comprehensive training programs, Bias equips staff with the skills required to meet evolving industry standards. This focus on human capital management drives the overall success of ProPharma Group by maintaining a highly skilled and motivated team dedicated to client excellence.